These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29657592)

  • 1. Design and baseline characteristics of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).
    Ogawa S; Minematsu K; Ikeda T; Kitazono T; Nakagawara J; Miyamoto S; Murakawa Y; Ohashi Y; Takeichi M; Okayama Y; Yamanaka S; Inuyama L
    J Arrhythm; 2018 Apr; 34(2):167-175. PubMed ID: 29657592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world outcomes of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).
    Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Miyamoto S; Murakawa Y; Takeichi M; Ohashi Y; Okayama Y; Sunaya T; Yamanaka S
    J Cardiol; 2019 Jul; 74(1):60-66. PubMed ID: 30745002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world outcomes of rivaroxaban treatment in patients with nonvalvular atrial fibrillation and worsening renal function.
    Nakagawara J; Ikeda T; Ogawa S; Kitazono T; Minematsu K; Miyamoto S; Murakawa Y; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    J Cardiol; 2019 Dec; 74(6):501-506. PubMed ID: 31371191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan.
    Miyamoto S; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Murakawa Y; Iwashiro S; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    J Stroke Cerebrovasc Dis; 2020 Apr; 29(4):104584. PubMed ID: 31983518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation.
    Kitazono T; Ikeda T; Ogawa S; Nakagawara J; Minematsu K; Miyamoto S; Murakawa Y; Cavaliere M; Hayashi Y; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    Heart Vessels; 2020 Mar; 35(3):399-408. PubMed ID: 31492970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation.
    Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; van Eickels M; Turpie AG
    Vasc Health Risk Manag; 2014; 10():425-34. PubMed ID: 25083135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS.
    Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Miyamoto S; Murakawa Y; Iwashiro S; Okayama Y; Sunaya T; Hirano K; Hayasaki T
    PLoS One; 2021; 16(6):e0251325. PubMed ID: 34115769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
    Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
    Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).
    Goodman SG; Wojdyla DM; Piccini JP; White HD; Paolini JF; Nessel CC; Berkowitz SD; Mahaffey KW; Patel MR; Sherwood MW; Becker RC; Halperin JL; Hacke W; Singer DE; Hankey GJ; Breithardt G; Fox KA; Califf RM;
    J Am Coll Cardiol; 2014 Mar; 63(9):891-900. PubMed ID: 24315894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).
    Sherwood MW; Douketis JD; Patel MR; Piccini JP; Hellkamp AS; Lokhnygina Y; Spyropoulos AC; Hankey GJ; Singer DE; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Becker RC;
    Circulation; 2014 May; 129(18):1850-9. PubMed ID: 24552831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
    Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
    Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke/Transient Ischemic Attack.
    Minematsu K; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Miyamoto S; Murakawa Y; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    Cerebrovasc Dis; 2019; 48(1-2):53-60. PubMed ID: 31578012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
    Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
    Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    Carter NJ; Plosker GL
    Drugs; 2013 May; 73(7):715-39. PubMed ID: 23677801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial.
    Wong KS; Hu DY; Oomman A; Tan RS; Patel MR; Singer DE; Breithardt G; Mahaffey KW; Becker RC; Califf R; Fox KA; Berkowitz SD; Hacke W; Hankey GJ;
    Stroke; 2014 Jun; 45(6):1739-47. PubMed ID: 24763930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –.
    Hori M; Matsumoto M; Tanahashi N; Momomura S; Uchiyama S; Goto S; Izumi T; Koretsune Y; Kajikawa M; Kato M; Ueda H; Iwamoto K; Tajiri M;
    Circ J; 2012; 76(9):2104-11. PubMed ID: 22664783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AF.
    Uchiyama S; Hori M; Matsumoto M; Tanahashi N; Momomura S; Goto S; Izumi T; Koretsune Y; Kajikawa M; Kato M; Ueda H; Iekushi K; Yamanaka S; Tajiri M;
    J Stroke Cerebrovasc Dis; 2014; 23(5):1142-7. PubMed ID: 24189454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J-ROCKET AF Trials) in Asian Patients With Atrial Fibrillation.
    Chan YH; Lee HF; Wang CL; Chang SH; Yeh CH; Chao TF; Yeh YH; Chen SA; Kuo CT
    J Am Heart Assoc; 2019 Nov; 8(21):e013053. PubMed ID: 31623498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF.
    van Diepen S; Hellkamp AS; Patel MR; Becker RC; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    Circ Heart Fail; 2013 Jul; 6(4):740-7. PubMed ID: 23723250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
    ROCKET AF Study Investigators
    Am Heart J; 2010 Mar; 159(3):340-347.e1. PubMed ID: 20211293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.